A:
Our portfolio consists of antibodies, cell lines, mouse models, plasmids and small molecules.
Read more
FAQ
Search our Frequently Asked Questions (FAQ) knowledge base to find the answers to your burning Ximbio questions.
Our mission has always been to develop Ximbio for the life sciences community.
If you can’t easily find the answers you need, you can also suggest a question that may help others
Categories
Couldn't find the answer to your question?
Ximbio is developed by the community, for the community we welcome your suggestions.
suggest an FAQRecently added FAQ
Q: Ximbio offer recombinant antibodies. What are their advantages over standard monoclonals?
A:
Recombinant antibodies (rAbs) have many advantages over traditional technologies. Produced to high purity levels there are low variations across different production batches and they can be manufactured in short time periods within animal free systems.
Read more
Q: Who is Ximbio for?
A:
Ximbio is designed and developed to support researchers and technology transfer offices, bench scientists, life science companies and the life sciences community in general.
Read more
Q: How does the Ximbio commercial model work?
A:
Ximbio operates a commercial deposit model with revenue sharing back to the depositing institutes.
Read more
Q: What is a licensing agreement?
A:
A licensing agreement is a legal contract between two parties, known as the licensor and the licensee
Read more
Q: What is a Material Transfer Agreement?
A:
A material transfer agreement (MTA) is a contract that governs the transfer of materials between institutions for use in research
Read more
Q: What does Ximbio do with the revenue it generates?
A:
Ximbio is a business unit of Cancer Research UK (CRUK), a proportion of any profits generated are shared with depositing institutions and the remainder used to fund further research.
Q: What happens after I submit a reagent to the website?
A:
Once you have submitted your reagent we will notify you of its deposit and a portfolio team member will be in contact to clarify any technical information and revenue model required.
Read more
Page 3 of 3